ClinicalTrials.gg
CompletedNCT06408870Updated Dec 1, 2025Results posted

A Study in Healthy People to Compare How 2 Different Low Dose Formulations of BI 1015550 Are Taken up in the Body

A Phase 1 interventional study of BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective of this trial is to establish the bioequivalence of the BI 1015550 Formulation C2 (Test, T) and the BI 1015550 Formulation C1 (Reference, R) following a single oral dose administration.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subject according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 50 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  • Signed and dated written in accordance with International Council for Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Female subject who meets any of the following criteria for a highly effective from at least 30 days before the first administration of trial medication until 7 days after last administration

Highly effective methods of contraception include:

  • Use of oral hormonal contraception that prevents ovulation, plus condom
  • Use of combined (estrogen and progestogen-containing) hormonal contraception that prevents ovulation (intravaginal or transdermal)
  • Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants)
  • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
  • Sexually abstinent is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject.
  • Bilateral tubal occlusion

    - Women not of (WNOCBP) include:

  • Permanently surgically sterilised (including hysterectomy, bilateral oophorectomy and bilateral salpingectomy)
  • , defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with levels of follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory) WNOCBP are not required to use any methods of contraception. For in vitro fertilization (IVF) and in foreign countries, female subjects should not participate in egg donation and male subjects should not participate in sperm donation from the first study drug administration, for the duration of the study and for at least 7 days after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre(s) of mercury (mmHg), diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 beats per minute (bpm) at screening
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, in particular, hepatic parameters ( (ALT), aspartate aminotransferase (AST), total ) or renal parameters (creatinine) exceeding the (ULN) at screening
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the investigator
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders including but not limited to depression and suicidal behaviour
  • History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    BI 1015550 Formulation C1 (Reference, R) then BI 1015550 Formulation C2 (Test, T)

    For this two period crossover study arm, participants received treatment in the following order: Participants received a single oral dose of nerandomilast (BI 1015550), a low dose film coated tablet (formulation C1, titanium dioxide \[TiO2\]-containing phase III formulation, reference (R)) with 240 mL water after an overnight fast of at least 10 h (period 1). Participants received a single oral dose of nerandomilast (BI 10105550), a low dose film coated tablet (formulation C2, titanium dioxide \[TiO2\] free, test (T)) with 240 mL water after an overnight fast of at least 10 h (period 2). In between the treatment periods, participants went through a washout period of 10 days.

    Drug: BI 1015550

  • Experimental
    BI 1015550 Formulation C2 (Test, T) then BI 1015550 Formulation C1 (Reference, R)

    For this two period crossover study arm, participants received treatment in the following order: Participants received a single oral dose of nerandomilast (BI 10105550), a low dose film coated tablet (formulation C2, titanium dioxide \[TiO2\] free, test (T)) with 240 mL water after an overnight fast of at least 10 h (period 1). Participants received a single oral dose of nerandomilast (BI 1015550), a low dose film coated tablet (formulation C1, titanium dioxide \[TiO2\]-containing phase III formulation, reference (R)) with 240 mL water after an overnight fast of at least 10 h (period 2). In between the treatment periods, participants went through a washout period of 10 days.

    Drug: BI 1015550

Interventions

  • Participants received two formulations of nerandomilast separated by a washout period

    Also known as: Nerandomilast

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

    Time frame: Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.

  2. Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)

    Maximum measured concentration of nerandomilast in plasma (Cmax) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

    Time frame: Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

    Time frame: Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.

07

Results

Posted Dec 1, 2025

Participant flow

The open-label, randomised, single-dose, two-way crossover study aimed to assess the bioequivalence of the BI 1015550 low dose Formulation C2 and the BI 1015550 low dose Formulation C1 (Phase 3 formulation) following oral administration in healthy subjects.

Treatment period 1
Participant flow — Treatment period 1
MilestoneBI 1015550 Formulation C1 (Reference, R) then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) then BI 1015550 Formulation C1 (Reference, R)
Started3232
Completed3232
Not completed00
Washout period
Participant flow — Washout period
MilestoneBI 1015550 Formulation C1 (Reference, R) then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) then BI 1015550 Formulation C1 (Reference, R)
Started3232
Completed2932
Not completed30
Withdrew: Withdrawal by subject10
Withdrew: Adverse event20
Treatment period 2
Participant flow — Treatment period 2
MilestoneBI 1015550 Formulation C1 (Reference, R) then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) then BI 1015550 Formulation C1 (Reference, R)
Started2932
Completed2932
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

Time frame:
Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.
Reported as:
Geometric least squares mean · hours*nanomole/Liter (hrs*nmol/L)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hours*nanomole/Liter (hrs*nmol/L)BI 1015550 Formulation C1 (Reference, R)BI 1015550 Formulation C2 (Test, T)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)1270.92 ± na1320.24 ± na
Statistical analysis
  • BI 1015550 Formulation C1 (Reference, R) vs BI 1015550 Formulation C2 (Test, T) · Ratio of adjusted geometric means [%]: 103.88 · 90% CI 101.08 to 106.75Ratio of adjusted geometric means \[%\] calculated as: test/reference\*100. Intra-individual pair geometric coefficient of variation (gCV) \[%\] = 9.0.
PrimaryMaximum Measured Concentration of Nerandomilast in Plasma (Cmax)

Maximum measured concentration of nerandomilast in plasma (Cmax) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

Time frame:
Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.
Reported as:
Geometric least squares mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)
nanomole/Liter (nmol/L)BI 1015550 Formulation C1 (Reference, R)BI 1015550 Formulation C2 (Test, T)
Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)218.84 ± na230.48 ± na
Statistical analysis
  • BI 1015550 Formulation C1 (Reference, R) vs BI 1015550 Formulation C2 (Test, T) · Ratio of adjusted geometric means [%]: 105.32 · 90% CI 100.83 to 110.01Ratio of adjusted geometric means \[%\] calculated as: test/reference\*100. Intra-individual pair geometric coefficient of variation (gCV) \[%\] = 14.5.
SecondaryArea Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is presented. The statistical model applied was an analysis of variance (ANOVA), with 'subjects within sequence' as a random effect and 'sequence,' 'period,' and 'treatment' as fixed effects.

Time frame:
Within 3 hours (hrs) prior to and at 15minutes (min), 30min, 45min, 1hrs, 1:15hrs, 1:30hrs, 1:45hrs, 2hrs, 2:30hrs, 3hrs, 3:30hrs, 4hrs, 6hrs, 8hrs, 12hrs, 24hrs, 34hrs, 48hrs, 58hrs, 72hrs, 96hrs, 120hrs, and 144hrs after nerandomilast intake.
Reported as:
Geometric least squares mean · hours*nanomole/Liter (hrs*nmol/L)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hours*nanomole/Liter (hrs*nmol/L)BI 1015550 Formulation C1 (Reference, R)BI 1015550 Formulation C2 (Test, T)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)1284.94 ± na1333.23 ± na
Statistical analysis
  • BI 1015550 Formulation C1 (Reference, R) vs BI 1015550 Formulation C2 (Test, T) · Ratio of adjusted geometric means [%]: 103.76 · 90% CI 100.95 to 106.65Ratio of adjusted geometric means \[%\] calculated as: test/reference\*100. Intra-individual pair geometric coefficient of variation (gCV) \[%\] = 9.1.

Adverse events

Collected over For all adverse events (AEs): From first nerandomilast intake until end of residual effect period (REP), up to 7 days. For all-cause mortality: From first nerandomilast intake until end of follow-up, up to 28 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1015550 Formulation C1 (Reference, R)0/64 (0%)0/64 (0%)15/64 (23.4%)
BI 1015550 Formulation C2 (Test, T)0/61 (0%)0/61 (0%)10/61 (16.4%)
Most frequent other events
Most frequent other events
EventBI 1015550 Formulation C1 (Reference, R)BI 1015550 Formulation C2 (Test, T)
HeadacheNervous system disorders12/6410/61
FatigueGeneral disorders4/640/61

Baseline characteristics

Treated set (TS): The treated set included all subjects who were treated with at least one dose of trial drug. The treated set was used for safety analyses.

Age, Continuous
Age, Continuous(Years)BI 1015550 Formulation C1 (Reference, R) Then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) Then BI 1015550 Formulation C1 (Reference, R)Total
Mean33.7 ± 8.135.5 ± 8.834.6 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)BI 1015550 Formulation C1 (Reference, R) Then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) Then BI 1015550 Formulation C1 (Reference, R)Total
Female61521
Male261743
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 1015550 Formulation C1 (Reference, R) Then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) Then BI 1015550 Formulation C1 (Reference, R)Total
Hispanic or Latino202
Not Hispanic or Latino303262
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1015550 Formulation C1 (Reference, R) Then BI 1015550 Formulation C2 (Test, T)BI 1015550 Formulation C2 (Test, T) Then BI 1015550 Formulation C1 (Reference, R)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White293160
More than one race202
Unknown or Not Reported000
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Aug 2024, 2 months.

Results were first posted in Dec 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
Jun 6, 2024
Primary completionActual
Aug 28, 2024
CompletionActual
Aug 28, 2024
Results first posted
Dec 1, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06408870
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jun 6, 2024
Primary completion
Aug 28, 2024
Completion
Aug 28, 2024
Results posted
Dec 1, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion